Trevi Therapeutics Announces Key Strategic Developments
Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company, has provided vital updates about its investigational therapy Haduvio™. Focused on treating chronic cough conditions in patients, Trevi is laying out its plans ahead of a notable industry event.
Upcoming Clinical Trials and Regulatory Meetings
As we look forward to 2026, Trevi is gearing up for a pivotal End-of-Phase 2 meeting with the FDA concerning its chronic cough program for patients affected by idiopathic pulmonary fibrosis (IPF). This meeting will define the development program that Trevi hopes to advance, particularly targeting chronic cough arising from IPF.
Focus on Refractory Chronic Cough
The company also shared its plans to launch a Phase 2b clinical trial to test Haduvio in patients suffering from refractory chronic cough (RCC) within the first half of the year. This dedication underscores Trevi's commitment to addressing the unmet medical needs of patients facing these challenging respiratory conditions.
Key Highlights from Trevi's Recent Announcements
Leadership at Trevi, including President and CEO Jennifer Good, expressed enthusiasm as they embark on these initiatives. With the chronic cough program front and center, the upcoming FDA meeting will be crucial in shaping the company’s roadmap ahead. Highlights of Trevi's announcements include:
- FDA Meeting for Chronic Cough in IPF: The company has scheduled an End-of-Phase 2 meeting with the FDA to discuss the New Drug Application for nalbuphine ER. This engagement is expected to facilitate the launch of Phase 3 trials in the first half of this year.
- Launch of Phase 2b Trial: The company is looking to initiate a Phase 2b trial for RCC patients, emphasizing the urgency and need for effective treatments.
- Leadership Participation: David Hastings, Trevi's new Chief Financial Officer, will actively participate in the upcoming LifeSci Partners Corporate Access Event alongside the senior management team.
About Haduvio and Its Impact on Patients
Haduvio is an innovative therapy designed specifically for individuals suffering from chronic coughs due to conditions like IPF and non-IPF interstitial lung disease (ILD). With a unique mechanism acting as a kappa agonist and mu antagonist (KAMA), Haduvio addresses not just the symptom but also works on the underlying cough reflex.
Currently, an estimated 150,000 people in the United States live with IPF, two-thirds of whom experience severe chronic cough. Notably, there are around 228,000 patients with non-IPF ILD, with 50-60% suffering from uncontrolled chronic cough. The significance of finding effective treatments cannot be understated, as these conditions can severely impact the quality of life for many individuals.
As Trevi prepares for upcoming trials, the company's commitment to addressing the chronic cough epidemic reflects a critical understanding of this pressing public health challenge.
Dedication to Clinical Advancement
With persistent cough being a debilitating condition, particularly in cases of RCC, characterized by lasting symptoms for over eight weeks, the need for innovative treatments remains high. Trevi Therapeutics’ determination to propose Haduvio as a viable option signals profound hope for millions affected by these chronic conditions.
This dedication is anchored in the belief that effective therapies should be accessible, as RC coughs have substantial physical, psychological, and social impacts on patients. Haduvio, under evaluation, aims to fill that gap and offer a much-needed solution.
Frequently Asked Questions
What is the purpose of Trevi Therapeutics' recent updates?
The updates inform about the company's strategic plans for Haduvio, focusing on chronic cough treatment in patients with IPF and RCC.
When is the FDA End-of-Phase 2 meeting scheduled?
The meeting is set to take place in early 2026.
What are Trevi's targets for the Phase 2b trial?
The trial aims to investigate Haduvio’s effectiveness in patients suffering from refractory chronic cough.
Who is leading the Trevi Therapeutics team?
Jennifer Good serves as the President and CEO, guiding the company’s initiatives and strategies.
What is the expected impact of Haduvio on patients?
Haduvio aims to significantly reduce cough frequency and improve the quality of life for patients suffering from chronic cough conditions.
